Though guidelines suggest screening starts at 50, researcher says it's premature to change them
This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
These encouraging data demonstrate the potential for olaparib to make a significant impact on the outcomes of patients with BRCA- deficient breast and ovarian cancer. AstraZeneca is fully evaluating the development of this drug in these diseases, and is exploring its potential in other populations of patients with cancers associated with defective DNA repair.
Thu Sep 08, 2011 07:37 PM
Hi I tried to get on the Parps trial but couldn't get on it because they thought the cancer was in my head but it isn't thsnk heavens but will get on them as soon as poosible as I have secondary breast cancer.
We care about your feedback. Let us know how we can improve your CancerCompass experience.